Developing innovative solutions to debilitating diseases
AdAlta’s i-body® drug discovery platform goes where antibodies do not, to create new options for debilitating diseases
- Using i-bodies – with antibody features at a fraction of the size
- Developing next generation protein and cell therapies – focused on fibrosis and immuno-oncology
- Lead asset AD-214 – first in class product for treating fibrotic diseases
- i-CAR-T cell therapies (reprogramming immune cells) – providing new hope for patients with solid tumours
- i-PET imaging – helping cancer patients know early if their immunotherapy is working
More Info
